XDx Gets CTAF Recommendation for AlloMap Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that the California Technology Assessment Forum has recommended the use of its AlloMap gene expression test.

The Brisbane, Calif.-based firm said that CTAF, which is a non-profit entity sponsored by Blue Shield of California to assess new and emerging medical technology, agreed that AlloMap met all five technology assessment criteria for safety, effectiveness, and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.